Diseases (Basel)
It is best understood as an emerging peptide research topic with potential relevance to gut inflammation, immune balance, and tissue-level inflammatory signaling
This combination is most often used in premium-positioned products such as recovery blends or anti-stress cellular health formulations
Cardiovascular Risk Reduction: With the 2023 approval for reducing major adverse cardiovascular events, GLP-1 receptor agonists are now used within comprehensive cardiovascular risk-management strategies for patients with type 2 diabetes and established cardiovascular disease
Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, et al
In addition, supplements with hard to break down nutrients may not be bioavailable